The 36-month beta value for CGTX is at 1.37. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for CGTX is 33.80M, and currently, shorts hold a 1.45% of that float. The average trading volume for CGTX on October 31, 2024 was 727.36K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CGTX) stock’s latest price update
The stock price of Cognition Therapeutics Inc (NASDAQ: CGTX) has dropped by -6.84 compared to previous close of 0.57. Despite this, the company has seen a fall of -11.50% in its stock price over the last five trading days. globenewswire.com reported 2024-10-29 that – Results show CT1812 dramatically slowed cognitive decline in patients with lower levels of plasma p-tau217, an important biomarker of Alzheimer’s disease pathology –
CGTX’s Market Performance
Cognition Therapeutics Inc (CGTX) has seen a -11.50% fall in stock performance for the week, with a 20.63% gain in the past month and a -41.00% plunge in the past quarter. The volatility ratio for the week is 16.84%, and the volatility levels for the past 30 days are at 12.08% for CGTX. The simple moving average for the past 20 days is 12.07% for CGTX’s stock, with a -65.53% simple moving average for the past 200 days.
Analysts’ Opinion of CGTX
Oppenheimer, on the other hand, stated in their research note that they expect to see CGTX reach a price target of $22. The rating they have provided for CGTX stocks is “Outperform” according to the report published on November 03rd, 2021.
B. Riley Securities gave a rating of “Buy” to CGTX, setting the target price at $27 in the report published on November 03rd of the previous year.
CGTX Trading at -2.64% from the 50-Day Moving Average
After a stumble in the market that brought CGTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.00% of loss for the given period.
Volatility was left at 12.08%, however, over the last 30 days, the volatility rate increased by 16.84%, as shares surge +17.74% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -30.63% lower at present.
During the last 5 trading sessions, CGTX fell by -11.50%, which changed the moving average for the period of 200-days by -74.35% in comparison to the 20-day moving average, which settled at $0.4737. In addition, Cognition Therapeutics Inc saw -71.30% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CGTX starting from Ricciardi Lisa, who purchase 5,700 shares at the price of $1.75 back on Mar 14 ’24. After this action, Ricciardi Lisa now owns 291,345 shares of Cognition Therapeutics Inc, valued at $9,975 using the latest closing price.
Stock Fundamentals for CGTX
Current profitability levels for the company are sitting at:
- -157.83 for the present operating margin
- 0.31 for the gross margin
The net margin for Cognition Therapeutics Inc stands at -83.55. The total capital return value is set at -2.5. Equity return is now at value -108.31, with -79.36 for asset returns.
Based on Cognition Therapeutics Inc (CGTX), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -36.63. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is -2096.93.
Currently, EBITDA for the company is -50.63 million with net debt to EBITDA at 0.55. When we switch over and look at the enterprise to sales, we see a ratio of -17.74. The receivables turnover for the company is 0.12for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.07.
Conclusion
In conclusion, Cognition Therapeutics Inc (CGTX) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
